VRTX – vertex pharmaceuticals incorporated (US:NASDAQ)

DELAYED
$ usd
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
1D
5D
1M
3M
YTD
1Y
3Y
1 Day VRTX SPY QQQ SPX
Date
Time
Symbol
Company Name
Action
%Chg
2/12/2026
04:01 pm
vrtx
vertex pharmaceuticals incorporated
BEAT
5.6%
11/3/2025
04:02 pm
vrtx
vertex pharmaceuticals incorporated
BEAT
-0.9%
8/4/2025
04:01 pm
vrtx
vertex pharmaceuticals incorporated
BEAT
-20.6%
5/5/2025
04:01 pm
vrtx
vertex pharmaceuticals incorporated
BEAT
-10.0%
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions?
The answers are right here.
Stock Stats
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Top News Gainers
3/12 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock. 8.1%
4/1 Form 8-K VERTEX PHARMACEUTICALS For: Apr 01 7.7%
3/4 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $271.00 price target on the stock. 7.6%
7/31 Q2/2019 6/30/2019 EPS 1.260 ZacksConsensus 0.750 ActVsEst 0.510 - Beat 7.6%
3/2 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Argus from $248.00 to $270.00. They now have a "buy" rating on the stock. 5.1%
3/28 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "buy" rating re-affirmed by analysts at Piper Sandler. They now have a $300.00 price target on the stock. 5.0%
10/19  Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia 4.1%
10/21 Form 8-K VERTEX PHARMACEUTICALS For: Oct 21 4.1%
4/6 Form SEC STAFF LETTER VERTEX PHARMACEUTICALS 3.8%
4/15 Form 4 VERTEX PHARMACEUTICALS For: Apr 13 Filed by: Silva Paul M 3.7%
Top News Decliners
1/30 Vertex Pharmaceuticals Inc (VRTX) Q4 2019 Earnings Call Transcript [The Motley Fool] -6.8%
4/7 The Vertex Foundation Commits $5 Million to Support Global COVID-19 Pandemic Response -6.2%
3/7 2 Biotech Stocks to Buy as Coronavirus Fears Tank the Market [The Motley Fool] -5.9%
4/28 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at Royal Bank of Canada from an "outperform" rating to a "sector perform" rating. -5.1%
3/17 Crispr: Beyond Gene-Editing [Seeking Alpha] -5.0%
4/21 Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI® (lumacaftor/ivacaftor) and SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Cystic Fibrosis Patients -4.4%
4/30 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at JMP Securities from $255.00 to $285.00. They now have a "market outperform" rating on the stock. -4.1%
2/26 Form 4 VERTEX PHARMACEUTICALS For: Feb 24 Filed by: WAGNER CHARLES F JR -3.8%
9/4 Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff [The Motley Fool] -3.7%
5/28 Form 4 VERTEX PHARMACEUTICALS For: May 24 Filed by: LEIDEN JEFFREY M -3.6%

Don’t Miss Out On The Next BIG Stock Move

Thanks for submitting the form.
VRTX – vertex pharmaceuticals incorporated (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
VRTX
SPY
QQQ
SPX
VRTX – vertex pharmaceuticals incorporated (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
VRTX SPY QQQ SPX
Stock Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Stock Stats
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
News
2/18
01:52 pm
vrtx
Low
Vertex Pharmaceuticals Stock: Is The Bull Run Over (Rating Downgrade) [Seeking Alpha]
2/17
04:00 pm
vrtx
Low
Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3
2/17
02:31 pm
vrtx
Low
Crispr: Emphasis Shifts To Cardiovascular Pipeline Amid Slow Casgevy Launch [Seeking Alpha]
2/17
10:04 am
vrtx
Low
Vertex Pharmaceuticals (NASDAQ:VRTX) was given a new $441.00 price target on by analysts at Canaccord Genuity Group Inc..
2/17
08:10 am
vrtx
Low
Vertex Pharmaceuticals (NASDAQ:VRTX) was given a new $591.00 price target on by analysts at HC Wainwright.
2/17
07:01 am
vrtx
Low
Vertex Pharmaceuticals (NASDAQ:VRTX) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
2/17
03:26 am
vrtx
Low
Vertex Pharmaceuticals Stock: Is Wall Street Bullish or Bearish? [Yahoo! Finance]
2/13
01:05 pm
vrtx
Low
Vertex Pharmaceuticals (NASDAQ:VRTX) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
2/13
11:12 am
vrtx
Low
Vertex Pharmaceuticals (NASDAQ:VRTX) had its "outperform" rating reaffirmed by analysts at Scotiabank.
2/12/2026
04:01 pm
vrtx
5.6%
BEAT
11/3/2025
04:02 pm
vrtx
-0.9%
BEAT
8/4/2025
04:01 pm
vrtx
-20.6%
BEAT
5/5/2025
04:01 pm
vrtx
-10.0%
BEAT
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions? The answers are right here.
2/17
10:56 am
Maintains
Hold
Hold
Canaccord Genuity
Low
-1.3%
2/17
10:48 am
Maintains
Overweight
Overweight
Barclays
Low
-1.1%
2/17
10:48 am
Maintains
Overweight
Overweight
Barclays
Low
-1.1%
2/17
07:01 am
Reiterates
Overweight
Overweight
Barclays PLC
Low
-2.6%
2/13
02:19 pm
Maintains
Sector Perform
Sector Perform
Scotiabank
Low
-2.1%
2/13
02:19 pm
Maintains
Sector Perform
Sector Perform
Scotiabank
Low
-2.1%
2/13
01:05 pm
Reiterates
Overweight
Overweight
Morgan Stanley
Low
-1.0%
2/13
01:05 pm
Reiterates
Overweight
Overweight
Morgan Stanley
Low
-1.0%
2/13
12:52 pm
Maintains
Outperform
Outperform
RBC Capital
Low
-0.9%
2/18
04:47 pm
vrtx
Low
Form 4 VERTEX PHARMACEUTICALS For: Feb 13 Filed by: WAGNER CHARLES F JR
2/18
04:44 pm
vrtx
Low
Form 4 VERTEX PHARMACEUTICALS For: Feb 13 Filed by: Tatsis Ourania
2/18
04:40 pm
vrtx
Low
Form 4 VERTEX PHARMACEUTICALS For: Feb 13 Filed by: Sachdev Amit
2/18
04:38 pm
vrtx
Low
Form 4 VERTEX PHARMACEUTICALS For: Feb 13 Filed by: McKechnie Duncan
2/18
04:35 pm
vrtx
Low
Form 4 VERTEX PHARMACEUTICALS For: Feb 13 Filed by: Kewalramani Reshma
2/18
04:32 pm
vrtx
Low
Form 4 VERTEX PHARMACEUTICALS For: Feb 13 Filed by: Bunnage Mark E.
2/18
04:29 pm
vrtx
Low
Form 4 VERTEX PHARMACEUTICALS For: Feb 13 Filed by: Bozic Carmen
2/18
04:26 pm
vrtx
Low
Form 4 VERTEX PHARMACEUTICALS For: Feb 13 Filed by: Biller Jonathan
2/18
04:24 pm
vrtx
Low
Form 4 VERTEX PHARMACEUTICALS For: Feb 13 Filed by: Bhatia Sangeeta N.
Show more
Top News Gainers
3/12 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock. 8.1%
4/1 Form 8-K VERTEX PHARMACEUTICALS For: Apr 01 7.7%
3/4 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $271.00 price target on the stock. 7.6%
7/31 Q2/2019 6/30/2019 EPS 1.260 ZacksConsensus 0.750 ActVsEst 0.510 - Beat 7.6%
3/2 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Argus from $248.00 to $270.00. They now have a "buy" rating on the stock. 5.1%
3/28 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "buy" rating re-affirmed by analysts at Piper Sandler. They now have a $300.00 price target on the stock. 5.0%
10/19  Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia 4.1%
10/21 Form 8-K VERTEX PHARMACEUTICALS For: Oct 21 4.1%
4/6 Form SEC STAFF LETTER VERTEX PHARMACEUTICALS 3.8%
4/15 Form 4 VERTEX PHARMACEUTICALS For: Apr 13 Filed by: Silva Paul M 3.7%
Top News Decliners
1/30 Vertex Pharmaceuticals Inc (VRTX) Q4 2019 Earnings Call Transcript [The Motley Fool] -6.8%
4/7 The Vertex Foundation Commits $5 Million to Support Global COVID-19 Pandemic Response -6.2%
3/7 2 Biotech Stocks to Buy as Coronavirus Fears Tank the Market [The Motley Fool] -5.9%
4/28 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at Royal Bank of Canada from an "outperform" rating to a "sector perform" rating. -5.1%
3/17 Crispr: Beyond Gene-Editing [Seeking Alpha] -5.0%
4/21 Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI® (lumacaftor/ivacaftor) and SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Cystic Fibrosis Patients -4.4%
4/30 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at JMP Securities from $255.00 to $285.00. They now have a "market outperform" rating on the stock. -4.1%
2/26 Form 4 VERTEX PHARMACEUTICALS For: Feb 24 Filed by: WAGNER CHARLES F JR -3.8%
9/4 Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff [The Motley Fool] -3.7%
5/28 Form 4 VERTEX PHARMACEUTICALS For: May 24 Filed by: LEIDEN JEFFREY M -3.6%